Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Renal Failure: Dose Adjustments

Renal Failure: Dose Adjustments

In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...

Antihypertensive Drugs: Direct Renin Inhibitors

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...

Renal Drug Excretion: Overview

Renal Drug Excretion: Overview

As primary excretory organs, the kidneys maintain homeostasis by removing waste substances from the bloodstream. They comprise over a million units called nephrons, which serve as the kidney's functional units.
A nephron consists of two primary structures: the renal corpuscle and the renal tubule. The renal corpuscle contains the glomerulus, a network of capillaries where the first step of renal excretion, glomerular filtration, occurs. Blood pressure forces water, ions, and small molecules out...

Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant

Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant

In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...

Renal Drug Excretion: Tubular Secretion

Renal Drug Excretion: Tubular Secretion

Active tubular secretion is a robust, energy-demanding process that utilizes carrier systems to transport drugs into renal tubules. The active renal secretion systems include the organic anion transporter (OAT) for weak acids and the organic cation transporter (OCT) for weak bases. Structurally similar drugs can compete for the same transporter, potentially leading to drug accumulation and toxicity. However, this principle can be exploited therapeutically. One example is probenecid (Probalan),...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Impact of renal denervation on circadian variations of blood pressure and clock gene expression in spontaneously hypertensive rats.

Frontiers in cardiovascular medicine·2026

Same author

Afferent Renal Denervation Attenuates Sympathetic Overactivation From the Paraventricular Nucleus in Spontaneously Hypertensive Rats.

American journal of hypertension·2024

Same author

Effect of Exercise Prescription Implementation Rate on Cardiovascular Events.

Frontiers in cardiovascular medicine·2022

Same author

[Association between high sensitivity C-reactive protein and contrast induced acute kidney injury in patients with acute coronary syndrome undergoing percutaneous coronary intervention: impact of atorvastatin].

Zhonghua xin xue guan bing za zhi·2012

Same author

[Transplantation of mesenchymal stem cells transfected with hepatocyte growth factor gene improves heart function in rats with heart failure].

Zhongguo ying yong sheng li xue za zhi = Zhongguo yingyong shenglixue zazhi = Chinese journal of applied physiology·2010

Same author

[Arresting effect of p16 and dll4 transfection on cell cycle of K562 cells].

Zhongguo shi yan xue ye xue za zhi·2010

Search research articles

Related Experiment Video

Updated: Jun 20, 2026

A Large Animal Model for Acute Kidney Injury by Temporary Bilateral Renal Artery Occlusion

A Large Animal Model for Acute Kidney Injury by Temporary Bilateral Renal Artery Occlusion

Published on: February 2, 2021

[Atorvastatin attenuated contrast induced renal function damage].

Guang-ling Chen¹, Jin-zi Su

¹Department of Cardiology, Affiliated First Hospital, Fujian Medical University, Fuzhou, China. cgling2005@yahoo.com.cn

Zhonghua Xin Xue Guan Bing Za Zhi

|September 29, 2009

Summary

This summary is machine-generated.

Atorvastatin pretreatment for coronary angiography patients reduces contrast-induced kidney damage and inflammation. This study shows atorvastatin (20 mg/qn) attenuates urinary protein excretion and preserves glomerular filtration rate (GFR).

More Related Videos

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

Published on: October 26, 2020

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

Related Experiment Videos

Last Updated: Jun 20, 2026

A Large Animal Model for Acute Kidney Injury by Temporary Bilateral Renal Artery Occlusion

A Large Animal Model for Acute Kidney Injury by Temporary Bilateral Renal Artery Occlusion

Published on: February 2, 2021

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

Published on: October 26, 2020

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

Area of Science:

Cardiology
Nephrology
Pharmacology

Background:

Coronary angiography frequently utilizes radiocontrast agents, which can induce acute kidney injury.
Inflammatory markers, such as high-sensitivity C-reactive protein (hsCRP), are elevated post-angiography.
Statins, including atorvastatin, possess pleiotropic effects beyond lipid-lowering, potentially offering renal protection.

Purpose of the Study:

To evaluate the efficacy of atorvastatin in preventing contrast-induced nephropathy (CIN) in patients undergoing coronary angiography.
To assess the impact of atorvastatin on plasma hsCRP levels as a marker of inflammation.
To investigate changes in urinary biomarkers of tubular and glomerular damage.

Main Methods:

A randomized controlled trial involving 120 patients undergoing coronary angiography.
Patients received either atorvastatin (20 mg/qn) or no atorvastatin 2-3 days prior to the procedure.
Renal function was assessed using serum creatinine, BUN, cystatin C, and calculated GFR; urinary alpha1-MG, TRF, and mALB measured tubular and glomerular damage; hsCRP levels monitored inflammation.

Main Results:

The control group exhibited significant increases in urinary biomarkers (alpha1-MG, TRF, mALB) and serum cystatin C post-angiography, indicating renal damage.
Atorvastatin pretreatment prevented significant changes in urinary biomarkers and serum cystatin C compared to baseline.
While hsCRP increased in both groups post-procedure, atorvastatin attenuated the overall inflammatory response and protected against tubular and glomerular damage.

Conclusions:

Low-dose contrast media can induce mild renal dysfunction.
Pretreatment with atorvastatin (20 mg/qn) for 2-3 days effectively mitigates procedural inflammatory responses.
Atorvastatin attenuates contrast-induced urinary protein excretion and preserves estimated GFR in patients undergoing coronary angiography.